Review posits Primary Biliary Cholangitis may become curable via T-cell modulation, nanoparticle tolerance, and epigenetics

Primary Biliary Cholangitis (PBC) is a chronic immune-mediated liver disease characterized by progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventual cirrhosis. Current therapeutic approaches primarily focus on maintenance and attenuating disease progression, largely within the bile acid space, rather than achieving a cure or reversing liver damage. This leaves a significant gap for patients who continue to progress despite standard care. Understanding and targeting the underlying autoimmune pathogenesis is crucial for developing curative strategies.

This review article extends the therapeutic discussion beyond conventional treatments for Primary Biliary Cholangitis, exploring paradigms rooted in autoimmune pathogenesis. The authors systematically reviewed existing literature and concepts from broader autoimmune diseases, contextualizing them with PBC-relevant data. They focused on identifying and discussing potential curative strategies, rather than merely attenuating disease progression. The scope included examining regulatory T-cell modulation, nanoparticle-based antigen-specific tolerance, and epigenetic factors like miRNA dysregulation.

The review highlights several promising avenues for achieving a cure in Primary Biliary Cholangitis. These include strategies centered on modulating regulatory T-cells, which are crucial for maintaining immune tolerance and preventing autoimmune attacks. Another paradigm involves inducing antigen-specific tolerance using nanoparticle-based delivery systems, aiming to retrain the immune system to ignore specific liver antigens and halt the destructive process. Epigenetic factors, particularly miRNA dysregulation and silencing of bicarbonate transporters, are also discussed as potential therapeutic targets that could reverse disease pathology. The authors also explored broader autoimmune concepts such as altered peptide ligands for T-cell deviation, decoy molecules, and antigen-specific T-cell suicide pathways, integrating these with existing PBC data.

The authors posit that by addressing the autoimmune pathogenesis directly, Primary Biliary Cholangitis may, in the future, be defined as a curable disease, moving beyond current maintenance-focused treatments.